[HTML][HTML] Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19
C Tisch, E Xourgia, A Exadaktylos, M Ziaka - Endocrine, 2024 - Springer
Objective SGLT-2i are increasingly recognized for their benefits in patients with
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …
cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications …
Re-examining the widespread policy of stopping SGLT2 inhibitors during acute illness: a perspective based on the updated evidence
Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors are now seen as an integral part of
therapy in type 2 diabetes to not only control blood glucose but to improve cardiovascular …
therapy in type 2 diabetes to not only control blood glucose but to improve cardiovascular …
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are now seen as an integral
part of therapy in type 2 diabetes to control not only blood glucose but to improve …
part of therapy in type 2 diabetes to control not only blood glucose but to improve …
[HTML][HTML] The Effect of Sodium–Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the …
KR Lim, KJ Chun, BS Kim, S Lee - Journal of Clinical Medicine, 2024 - mdpi.com
Background: There is no clinical evidence about the effect of sodium–glucose cotransporter-
2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus …
2 (SGLT2) inhibitors on diabetic patients who have been diagnosed with coronavirus …
[HTML][HTML] Sodium-glucose co-transporter 2 inhibitors in COVID-19: Meeting at the crossroads between heart, diabetes and infectious diseases
T Koufakis, AN Pavlidis, S Metallidis… - International Journal of …, 2021 - Springer
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering
agents which have changed the landscape of diabetes therapy, due to their remarkable …
agents which have changed the landscape of diabetes therapy, due to their remarkable …
[HTML][HTML] Sodium–glucose cotransporter 2 inhibitors and major COVID-19 outcomes: promising mechanisms, conflicting data, and intriguing clinical decisions
Dear Editor, In their anecdotal report, Bossi and colleagues demonstrate that ''off-label''use
of sodium–glucose cotransporter2 (SGLT2) inhibitors in three subjects with severe or critical …
of sodium–glucose cotransporter2 (SGLT2) inhibitors in three subjects with severe or critical …
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review …
Aims This study aims to examine the effectiveness of using sodium glucose transporter-2
inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients …
inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients …
SGLT2 inhibition during the COVID-19 epidemic: friend or foe?
AJ Scheen - Diabetes & metabolism, 2020 - Elsevier
Type 2 diabetes mellitus (T2DM) is a risk factor for severe illness related to COVID-19
(Coronavirus Disease 2019), and is associated with at least a twofold increased mortality …
(Coronavirus Disease 2019), and is associated with at least a twofold increased mortality …
Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: a population‐based retrospective cohort study
Abstract Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are widely prescribed in
people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is …
people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is …
Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-19: a systematic review and network meta-analysis
Z Zhu, Q Zeng, Q Liu, J Wen, G Chen - JAMA Network Open, 2022 - jamanetwork.com
Importance Patients with COVID-19 have a high prevalence of diabetes, and diabetes and
blood glucose control are determinants of intensive care unit admission and mortality …
blood glucose control are determinants of intensive care unit admission and mortality …